TabletsClinical Overview
Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily after breakfast or with water, at the same time each day. Swallow whole without crushing or chewing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, flushing, headache, mild palpitations, nausea, rash. Rare/Severe: Severe hypotension, excessive bradycardia, and elevation of liver enzymes.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with severe cardiogenic shock or advanced aortic stenosis. Safe alternative in patients experiencing refractory pedal edema from amlodipine. Caution in severe hepatic impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Cilnidipine Tablets 20mg
Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.
Cilnidipine 10mg + Telmisartan 40mg Tablets
Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.
Cilnidipine Tablets 5 mg
Cilnidipine is a novel fourth-generation calcium channel blocker with unique dual L-type and N-type voltage-gated calcium channel antagonist properties. While L-type blockade dilates vascular smooth muscle, N-type blockade at sympathetic nerve terminals inhibits the pathological release of norepinephrine, suppressing sympathetic nervous hyperactivity, preventing reflex tachycardia, and dilating both afferent and efferent renal arterioles to lower intraglomerular hydrostatic pressure. Indicated for essential hypertension, particularly in patients with morning hypertension, diabetic nephropathy, chronic kidney disease, or ankle edema from amlodipine.
Telmisartan 80mg + Cilnidipine 10mg Tablets
Telmisartan and Cilnidipine is an innovative vascular- and renal-protective antihypertensive combination. Telmisartan blocks AT1 angiotensin receptors, while cilnidipine acts as a unique dual L-type and N-type voltage-gated calcium channel blocker. Blockade of sympathetic N-type calcium channels on sympathetic nerve endings inhibits excessive norepinephrine release, preventing reflex tachycardia and dilating both efferent and afferent renal arterioles, which lowers intraglomerular pressure and reduces proteinuria with virtually zero incidence of pedal edema. Indicated for essential hypertension, particularly in patients with metabolic syndrome, diabetes, or renal impairment.